Yiteng Jiahe: The adjustment involves collaboration on siRNA assets, with the ANGPTL3 asset rights expanded globally

LightningPacketLoss · 2026-03-06T13:24:25+00:00

Yiteng Jiahe and Nati De signed a supplemental and termination agreement, expanding the licensing territory of siRNA asset ANGPTL3 to the global market, thereby increasing the company's value. The ANGPTL3 candidate drug EDP167 completed the first dosing in Phase II clinical trials. The company terminated two other preclinical siRNA asset collaborations, which are not expected to have a significant impact on the business.

LightningPacketLoss

2026-03-06 13:24:25

Abstract generation in progress

Recently, Yiteng Jiahe announced that it has signed a supplemental agreement and a termination agreement with Nati De (Qingdao) Biomedical Co., Ltd., mainly involving adjustments to the siRNA asset collaboration.

According to the new agreement, the licensing area for one of the siRNA assets, ANGPTL3, has been expanded from the original region to a global scope. This will enhance the asset’s value for the company and help increase long-term shareholder value. Additionally, the candidate drug EDP167 for ANGPTL3 has successfully completed the first dosing in Phase II clinical trials.

Furthermore, considering the competitive market environment, the company has decided to terminate collaborations for two other preclinical siRNA assets. Since these assets are still in early development stages, the termination is not expected to have a significant adverse impact on the company’s business, financial condition, or operations.

(Yiteng Jiahe Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.